|
|
Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women |
|---|---|
| Author: | Mosorin, Maria-Elina1; Haverinen, Annina2; Ollila, Meri-Maija1; |
| Organizations: |
1Department of Obstetrics and Gynecology, Oulu University Hospital, University of Oulu and Medical Research Center, and PEDEGO Research Unit (Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology), Oulu, Finland 2Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 3Center for Life Course Health Research, University of Oulu, Oulu, Finland
4Medical Research Center Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
5Unit of General Practice, Oulu University Hospital, Oulu, Finland 6Nordlab Oulu, Medical Research Center Oulu, Oulu University Hospital and Department of Clinical Chemistry, University of Oulu, Oulu, Finland 7Center for Life Course Health Research, University of Oulu, Oulu, Finlan |
| Format: | article |
| Version: | accepted version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 0.2 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2022031623824 |
| Language: | English |
| Published: |
Bioscientifica,
2020
|
| Publish Date: | 2022-03-16 |
| Description: |
AbstractObjective: The use of combined hormonal contraceptives (CHCs) worsens glucose tolerance, but the risk for glucose metabolism disorders remains controversial. Design: The study is a prospective longitudinal population-based cohort study. Methods: The study was based on a cohort population that comprised 1879 women born in 1966. At age 46, the women answered a questionnaire on contraceptive use and underwent an oral glucose tolerance test. Glucose metabolism indices were evaluated in current CHC (n = 153), progestin-only contraceptive (POC, n = 842), and non-hormonal contraceptive users (n = 884). Results: In the entire study population, current CHC use was significantly associated with prediabetes (OR: 2.0, 95% CI: 1.3–3.2) and type 2 diabetes (OR: 3.3, 95% CI: 1.1–9.7) compared to non-hormonal contraceptive use. After 5 years of use, the prediabetes risk increased 2.2-fold (95% CI: 1.3–3.7) and type 2 diabetes risk increased 4.5-fold (95% CI: 1.5–13.5). Compared with the current POC use, current CHC use was significantly associated with prediabetes (OR: 1.9, 95% CI: 1.2–3.0). Current POC use was not associated with any glucose metabolism disorders. The results prevailed after adjusting for BMI and socioeconomic status. Conclusions: CHC use in perimenopausal women was associated with a significantly increased risk of glucose metabolism disorders. This association should be considered in women with increased metabolic risk. see all
|
| Series: |
European journal of endocrinology |
| ISSN: | 0804-4643 |
| ISSN-E: | 1479-683X |
| ISSN-L: | 0804-4643 |
| Volume: | 183 |
| Issue: | 6 |
| Pages: | 619 - 626 |
| DOI: | 10.1530/EJE-20-0406 |
| OADOI: | https://oadoi.org/10.1530/EJE-20-0406 |
| Type of Publication: |
A1 Journal article – refereed |
| Field of Science: |
3123 Gynaecology and paediatrics |
| Subjects: | |
| Funding: |
This study was supported by grants from the Sigrid Jusélius Foundation, the Academy of Finland, Oulu and Helsinki University Hospital Research Funds, and Oulu University Medical Research Center. |
| Copyright information: |
© 2020 European Society of Endocrinology. The final authenticated version is available online at https://doi.org/10.1530/EJE-20-0406. |